Source: StreetInsider

Press Release: EnGeneIC : EnGeneIC granted FDA "Fast-Track" Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic

SYDNEY, Australia and NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- EnGeneIC, an innovative biopharmaceutical company leading the field of armed antibody therapeutics for oncology, has achieved a significant milestone with the granting of FDA Fast-Track designation...

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Himanshu Brahmbhatt's photo - Co-CEO of EnGeneIC

Co-CEO

Himanshu Brahmbhatt

CEO Approval Rating

68/100

Read more